Trypanosoma cruzi is a blood and tissue parasite that affects millions of individuals causing significant human morbidity and mortality. Basic understanding of the role of the critical surface molecules that participate in the first step of T. cruzi infection may provide novel targets for therapy. Our long-range goal is to understand the molecular mechanisms that allow T. cruzi to infect mammalian cells and cause disease, so that specific molecular intervention strategies can be developed against T. cruzi infection. The objective of this application is to identify which host cell receptors mediate T. cruzi binding to mammalian cells, when receptor-mediated signaling pathways contribute to infection. The hypothesis of this application is that T. cruzi gp83, a ligand molecule that the parasite uses to attach to mammalian cells, binds to the lectin-like oxidized low-density lipoprotein receptor (LOX-1) of mammalian host cells to mediate trypanosome attachment, thereby activating signaling events leading to initial infection and pathogenesis. We have formulated this hypothesis based on strong preliminary results, showing that interruption of LOX-1 gene by gene trapping or silencing LOX-1 gene by RNAi inhibits T. cruzi binding to cells and infection, whereas over-expression of LOX-1 in cells causes over-attachment of trypanosomes to cells and increased infection. Supporting also this hypothesis are our findings showing that gp83 specifically binds to LOX-1 and that we have identified critical regions on gp83 and LOX-1 that interact with each other to apparently mediate T. cruzi attachment leading to parasite entry. We will test our central hypothesis by pursuing the following specific aims: (1) to determine the structural-function relationships of the LOX-1-gp83 interaction;(2) to determine the LOX-1- dependent signaling pathways that mediate trypanosome gp83-dependent infection;and (3) to determine the in vivo role of the LOX-1 gene in the process of T. cruzi infection and pathogenesis using a novel LOX-1 knock out mouse model and a novel transgenic mouse model over-expressing LOX-1. Mutations, deletions and substitutions in critical regions of LOX-1 and gp83 will be performed to identify the motifs in each interacting molecule involved in T. cruzi binding to cells. Computational modeling of the trypanosome gp83 and the interacting peptide loop from the extracellular domain of LOX-1 will be determined. The mechanism underlying the novel gp83-LOX-1 signal transduction pathway leading to regulation of laminin ?-1 expression and infection will be elucidated using LOX-1(-/-) cells and LOX(+/+) cells. We will use our novel mouse models that over-express LOX-1 or that are null for LOX-1 expression to provide definitive in vivo tools to understand the other complementary mechanisms that contribute to trypanosome infection (in the LOX-1 null animals) and the mechanisms by which LOX-1 mediates infection (in the over-expressing animals).

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Enhancement Award (SC1)
Project #
5SC1AI080580-04
Application #
7906721
Study Section
Special Emphasis Panel (ZGM1-MBRS-8 (BV))
Program Officer
Mcgugan, Glen C
Project Start
2007-09-01
Project End
2013-08-31
Budget Start
2010-09-01
Budget End
2013-08-31
Support Year
4
Fiscal Year
2010
Total Cost
$355,699
Indirect Cost
Name
Meharry Medical College
Department
Microbiology/Immun/Virology
Type
Other Domestic Higher Education
DUNS #
041438185
City
Nashville
State
TN
Country
United States
Zip Code
37208
Dotson, Dominique; Woodruff, Elvin A; Villalta, Fernando et al. (2016) Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression. J Biol Chem 291:4236-46
Udoko, Aniekanabassi N; Johnson, Candice A; Dykan, Andrey et al. (2016) Early Regulation of Profibrotic Genes in Primary Human Cardiac Myocytes by Trypanosoma cruzi. PLoS Negl Trop Dis 10:e0003747
Matthews, Qiana L; Farrow, Anitra L; Rachakonda, Girish et al. (2016) Epitope Capsid-Incorporation: New Effective Approach for Vaccine Development for Chagas Disease. Pathog Immun 1:214-233
Lepesheva, Galina I; Hargrove, Tatiana Y; Rachakonda, Girish et al. (2015) VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis. J Infect Dis 212:1439-48
Haubrich, Brad A; Singha, Ujjal K; Miller, Matthew B et al. (2015) Discovery of an ergosterol-signaling factor that regulates Trypanosoma brucei growth. J Lipid Res 56:331-41
Friggeri, Laura; Hargrove, Tatiana Y; Rachakonda, Girish et al. (2014) Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14?-demethylase: two regions of the enzyme molecule potentiate its inhibition. J Med Chem 57:6704-17
Farrow, Anitra L; Rachakonda, Girish; Gu, Linlin et al. (2014) Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection. PLoS Negl Trop Dis 8:e3089
Johnson, Candice A; Rachakonda, Girish; Kleshchenko, Yuliya Y et al. (2013) Cellular response to Trypanosoma cruzi infection induces secretion of defensin ?-1, which damages the flagellum, neutralizes trypanosome motility, and inhibits infection. Infect Immun 81:4139-48
Villalta, Fernando; Dobish, Mark C; Nde, Pius N et al. (2013) VNI cures acute and chronic experimental Chagas disease. J Infect Dis 208:504-11
Nde, Pius N; Lima, Maria F; Johnson, Candice A et al. (2012) Regulation and use of the extracellular matrix by Trypanosoma cruzi during early infection. Front Immunol 3:337

Showing the most recent 10 out of 24 publications